Trial Search Results

Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)

This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Matthew Neal MD

Collaborator: National Heart, Lung, and Blood Institute (NHLBI)


  • Drug: theraputic heparin
  • Drug: prophylactic heparin
  • Drug: P2Y12


Phase 4


Inclusion Criteria:

   - ≥ 18 years of age

   - Hospitalized for COVID-19

   - Enrolled within 72 hours of hospital admittance or 72 hours of positive COVID test

   - Expected to require hospitalization for > 72 hours

Exclusion Criteria:

   - Imminent death

   - Requirement for chronic mechanical ventilation via tracheostomy prior to

   - Pregnancy

      - Based on a recommendation from the ACTIV4 DSMB on December 19, 2020, enrollment
      of patients requiring ICU level of care into the therapeutic anti-coagulation arm
      was stopped due to meeting a futility threshold and a potential for harm for this
      sub-group could not be excluded. Enrollment continues for moderately ill
      hospitalized COVID-19 patients.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305